Bristol Myers boosted its 2026 sales forecast after the company saw strong demand for its new drugs in the third quarter, including the cancer treatment Opdivo Qvantig
Bristol Myers Squibb is using Copilot and agents to help bring more medicines to more patients faster.
Across its 30,000-person enterprise, the company has reached 96% Microsoft 365 Copilot adoption and has 25,000 agents in use. One agent has helped project managers save up to 20% of their time, while teams apply the same foundation across R&D and core business work.
See how BMS is scaling new ways of working around patients:
Bristol Myers has reported a death in its clinical trials of an experimental cell therapy for autoimmune diseases, potentially adding to safety concerns about a promising new class of treatments.
BRISTOL-MYERS SQUIBB COMPANY SAYS CORR 40.5% FOR IZA-BREN VS 20.2% FOR CHEMOTHERAPY; MDOR 6.9 VS 4.2 MONTHS; IZA-BREN REDUCES RISK OF PROGRESSION OR DEATH BY 59% IN PHASE 3 BREAST CANCER STUDY
BRISTOL -MYERS SQUIBB COMPANY SAYS MEDIAN PFS 8.2 MONTHS FOR IZA-BREN VS 4.0 MONTHS FOR CHEMOTHERAPY IN PHASE 3 STUDY; IZA-BREN DEMONSTRATES CLINICAL BENEFIT IN FIVE DISTINCT TUMOR TYPES
Bristol Myers' experimental drugs for treating a rare endocrine cancer and a deadly form of lung disease succeeded in late-stage studies, boosting the pharmaceutical company’s new product pipeline
Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.